Traction and market
Every year Aphasia affects approximately 5 million people worldwide. About ¼ of them is below 40 years old. Such number of patients has an immense impact on healthcare systems and societies. Currently offered therapy is lengthy, expensive an often ineffective.
Just in the USA and EU, almost half a million patients who are in immediate need of the effective therapy would benefit from our product annually. On the global market, it has the potential to help millions of people a year and alleviate great expenditures of healthcare systems.
Based on scientific evidence, it is estimated that brain stimulation applied by our device can significantly rise treatment success rate. Thanks to the increased efficiency of the treatment, the medical centers could serve up to 3 times more patients, resulting in significant savings in medical staff. Moreover, the cheaper the treatments and increased recovery rates the lower healthcare system expenditures and amounts of health-related pensions paid to the people who suffer from Aphasia (in EU, the savings could reach €3 billion every year).